Table 5b.
Summary of the VABS-II Total Score (mITT Population)
| VABS-II Score | Placebo (N=6) |
ELND005 250 mg BID (N=12) |
ELND005 250 mg QD (N=4) |
|---|---|---|---|
|
| |||
| Baseline | |||
| Mean (SD) | 682.3 (60.9) | 660.5 (49.1) | 690.0 (31.8) |
| Median | 687.0 | 666.0 | 691.0 |
| Range | 597.0–775.0 | 550.0–736.0 | 652.0–726.0 |
|
| |||
| Week 4 | |||
| Mean (SD) | 674.3 (48.9) | 672.6 (53.7) | 683.3 (32.0) |
| Median | 689.5 | 659.5 | 681.5 |
| Range | 594.0–716.0 | 565.0–749.0 | 650.0–720.0 |
|
| |||
| Week 4 CFB | |||
| Mean (SD) | −8.0 (26.0) | 12.1 (31.2) | −6.8 (32.7) |
| Median | 0.5 | 12.5 | 3.0 |
| Range | −59.0 – 13.0 | −25.0–82.0 | −53–20.0 |